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Abstract Mismatch repair plays a critical role in genome
stability. This process requires several proteins including
hMSH2/hMSH6 (hMutSK) heterodimer involved in the ¢rst
stage of the process, the mispair recognition. We previously
reported that in U937 and HL-60 cell lines, hMSH2 and
hMSH6 protein expression was much lower than that in
HeLa and KG1a cells. Here, we showed that the decreased
expression of hMutSK results from di¡erences in the degrada-
tion rate of both proteins by the ubiquitin-proteasome pathway.
Our data suggest that in human cell lines, ubiquitin-proteasome
could play an important role in the regulation of hMutSK pro-
tein expression, thereby regulating mismatch repair activity.
2 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Cancer cells are characterized by multiple genetic abnor-
malities that could interfere with cell growth, di¡erentiation,
motility and sensitivity to chemotherapy. These observations
suggest that the mechanisms controlling genetic stability could
be altered in cancer cells [1]. An example of tumors displaying
mismatch repair (MMR) dysfunction is given by inherited
familial cancer syndrome of hereditary non-polyposis colon
cancers [2]. MMR plays an important role in the maintenance
of genomic integrity by correcting replicative mismatches (nu-
cleotide mispairs, insertion/deletion loops) that escape DNA
polymerase proofreading [3]. MMR activity begins with mis-
match recognition either by hMutSK, a heterodimer of
hMSH2 and hMSH6 proteins, or by hMutSL (a heterodimer
of hMSH2 and hMSH3). A second complex hMutLK (a het-
erodimer of hMLH1 and hPMS2) that facilitates mismatch
correction is then recruited. Strand discrimination and degra-
dation of the strand carrying the wrong base occur prior to
DNA strand gap repair synthesis. Defective MMR is charac-
terized by the production of multiple replication errors in
repetitive DNA sequences (microsatellites), leading to micro-
satellite instability (MSI), and an elevated rate of spontaneous
mutations, resulting in a mutator phenotype.
MSI is related to absent or weak expression of MMR pro-
teins that does not always result from MMR gene mutation or
promoter methylation [4^6]. Previous studies have established
that hMutSK proteins can be regulated at the transcriptional
level and that AP1 and p53 are involved in gene regulation [7^
9]. However, hMSH2 and hMSH6 protein expression does not
always correlate with mRNA levels [10,11]. One possible
mechanism for regulation of protein expression is proteolysis
by the ubiquitin-proteasome (Ub-proteasome) pathway [12].
This process results from the covalent conjugation of Ub to
proteins, catalyzed by a family of Ub-conjugating and Ub-
ligating enzymes. The ubiquitinated proteins can be further
degraded by the 26S proteasome constituted by a catalytic
complex (20S) and two regulator complexes (19S). Ub-protea-
some regulates several DNA repair processes by degrading
various proteins, including p53 [13], XPC [14], and MGMT
[15].
We showed recently that di¡erent hMutSK protein levels
were found in various cell lines [16]. In this paper, we inves-
tigated whether the Ub-proteasome pathway could be in-
volved in the regulation of hMutSK protein expression.
2. Materials and methods
2.1. Cells and chemicals
U937 (monocytic), HL-60 (myelocytic), KG1a (promyeloblastic),
HeLa (epithelial), and MRC-5 (¢broblast) cell lines were obtained
from the ATCC (Rockville, MD, USA). U937 and HL-60 cell lines
were grown in RPMI 1640 containing 10% fetal calf serum (FCS).
KG1a cells were grown in IMDM containing 20% FCS. HeLa and
MRC-5 cell lines were grown in MEM containing 10% FCS. Culture
media were supplemented with 2 mM glutamine, streptomycin (100
Wg/ml) and penicillin (200 U/ml). All other reagents were purchased
from Sigma-Aldrich (St Quentin-Fallavier, France).
2.2. Immunoprecipitation and Western blot analysis
For immunoprecipitation, cell extracts were incubated overnight at
4‡C with anti-MSH6 (Transduction Laboratories, Lexington, KY,
USA), anti-MSH2 (Oncogene Research Products, Boston, MA,
USA) or anti-Ub (Zymed, San Francisco, CA, USA) antibodies. Sam-
ples were separated by 7.5% sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE), transferred onto nitrocellulose
membranes and probed with anti-MSH2 (1 Wg/ml), anti-MSH6
(1 Wg/ml), anti-Ub (1 Wg/ml) or anti-L-actin (2 Wg/ml) (Chemicon,
Temecula, CA, USA) antibodies. Detection was performed with the
enhanced chemiluminescence system ECL Kit (Amersham Pharmacia
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Biotech, Saclay, France). The quanti¢cation of protein expression
levels was done by the NIH Image software.
2.3. Real-time quantitative polymerase chain reaction (PCR)
Total cellular RNA was extracted with TRIzol0. Reverse transcrip-
tion of total RNA was performed with the SuperScript1 First-Strand
Synthesis System for RT-PCR (Invitrogen1 Life Technologies, Cergy
Pontoise, France). Forward and reverse primers were designed using
Primer Input 3 for each gene of interest (Table 1). Real-time PCR was
performed using an iCycler thermal cycler (Bio-Rad, Marnes-la-Co-
quette, France) according to the manufacturer’s instructions. Reac-
tions were performed with 0.3 WM primers. Nucleotides, Taq DNA
polymerase, and bu¡er were included in SYBR Green JumpStart1
Taq ReadyMix1 for quantitative PCR. cDNA ampli¢cation consisted
of one cycle at 95‡C for 1 min 30 s, followed by 40 cycles of dena-
turation at 95‡C for 15 s and annealing and extension at 60‡C for
1 min. The threshold cycle (CT) values were determined by iCycler
software (Bio-Rad) and the quanti¢cation data were analyzed follow-
ing the vvCT method using L-actin as reference. We have checked
that PCR e⁄ciency (E) of the ampli¢cation was similar whatever
the primers and we calculated the relative amount (RA): RA ¼
ð1þ EÞ3vvCT .
2.4. In vitro determination of proteasome activity
The in vitro activity of the 20S proteasome was determined accord-
ing to Grune et al. [17]. Cells were re-suspended in phosphate-bu¡ered
saline containing 0.1% Triton X-100 and 0.5 mM dithiothreitol
(DTT), homogenized and used immediately for measuring the enzy-
matic activity. The assay mixture contained 50 mM Tris^HCl pH 7.8,
20 mM KCl, 5 mM MgCl2, 0.1 mM DTT, 250 WM sLLVY-MCA and
50 Wg of proteins. After 1 h at 37‡C, the reaction was stopped by
adding 1 ml of 0.2 M glycine bu¡er pH 10. The £uorescence of the
proteolytically released 7-amino-4-methylcoumarin (MCA) was ex-
cited at 370 nm and the emission was recorded at 460 nm.
2.5. Degradation assay
Degradation of hMutSK proteins was determined on cell homoge-
nates using minor modi¢cations of the method described previously
[18]. Brie£y, cell extracts were prepared by addition of lysis bu¡er.
Anti-MSH2 and anti-MSH6 immunocomplexes recovered by binding
to protein G-Sepharose beads were used as substrates for in vitro
degradation. The degradation reaction included immunoprecipitates,
100 Wg of rabbit reticulocyte lysate (RRL) as a source of Ub-protea-
some factors, and 2 mM ATP, 1 mM creatine phosphate, 25 U/ml
creatine phosphokinase and 0.1 Wg/ml Ub. Where indicated MG132
(50 WM) was added. The degradation mixture was incubated for 90
min at 30‡C. The samples were eluted by boiling in 1ULaemmli bu¡-
er, and separated by a 7.5% SDS^PAGE, transferred onto nitrocellu-
lose membranes, and incubated with anti-MSH2 and anti-MSH6 anti-
bodies.
3. Results
3.1. hMSH2 and hMSH6 expression in human cells
We compared hMSH2 and hMSH6 protein levels in di¡er-
ent cell lines (U937, HL-60, KG1a, MRC-5 and HeLa cells).
hMSH2 and hMSH6 protein expression was very low in U937
and HL-60 cells, compared to that in KG1a, MRC-5 and
HeLa cells (Fig. 1A). We ¢rst investigated the possibility of
a transcriptional regulation, but real-time quantitative PCR
analyses revealed no signi¢cant di¡erences in hMSH2 and
hMSH6 mRNA levels between the di¡erent cell lines (Fig.
1B).
Thus, the di¡erences in hMutSK protein expression result
from post-transcriptional processes and we hypothesized an
involvement of di¡erences in protein stability in the di¡erent
cell lines.
3.2. hMSH2 and hMSH6 protein stability in human cell lines
We determined hMSH2 and hMSH6 protein stability in
U937, HL-60, KG1a, MRC-5 and HeLa cell lines, following
inhibition of de novo protein synthesis resulting from cell
treatment with cycloheximide (CHX) (Fig. 2). In U937 and
HL-60 cell lines, hMSH2 and hMSH6 protein levels markedly
decreased with time. In contrast, only a weak degradation was
observed in KG1a and HeLa cell lines while the degradation
rate in MRC-5 cells was in between (Fig. 2A). Densitometric
analysis showed that half-lives of hMutSK components in
U937 cells were about 14 h and 12.5 h, respectively and
even shorter in HL-60 cells (about 8 h and 7.5 h, respectively)
compared to KG1a, MRC-5 and HeLa cells (longer than 20 h)
(Fig. 2B). In all cell lines, the half-lives of the two proteins
were strongly correlated.
These results showed that the hMutSK degradation rates
were cell-dependent and inversely correlated with hMutSK
protein expression levels.
Table 1
Oligonucleotide primer sequences for real-time quantitative PCR
Target gene Forward primer (5P-3P) Reverse primer (5P-3P) Size (bp) Tm E
hMSH2 AAGGCTTCTCCTGGCAATCT CACAACACCAATGGAAGCTG 81 80.9 94.4
hMSH6 AGACTTGGTGCCTCAGACAGA TCATCCACAAGCACCAGAGA 116 81.8 93.9
L-Actin TCCCTGGAGAAAGAGCTACGA AGGAAGGAAGCCTGGAAGAG 98 87.2 92.3
The length of the speci¢c ampli¢cation products, their approximate melting temperature (Tm) (‡C) and their PCR e⁄ciency (E) are indicated.
Fig. 1. A: Expression of hMSH2 and hMSH6 proteins in di¡erent
human cell lines. L-Actin was used as loading control. B: Expres-
sion of hMSH2 and hMSH6 mRNA measured by real-time quanti-
tative PCR in human cell lines. The data are expressed as the rela-
tive amounts compared with values from U937 cells. The results are
the mean (W S.D.) of three independent experiments.
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3.3. hMutSK proteins are degraded by the proteasome pathway
In order to investigate the mechanisms of degradation of
hMutSK proteins, we used di¡erent protease inhibitors. U937
cells were pretreated for 1 h with a caspase inhibitor (Z-VAD-
FMK), serine protease inhibitors (dichloroisocoumarin (DCIC)
or 1-chloro-3-tosylamido-4-phenyl-2-butanone (TPCK)), a cal-
pain inhibitor (calpeptin), or proteasome inhibitors (MG132
or lactacystin), then treated with CHX for 20 h. In the ab-
sence of de novo protein synthesis, cell pretreatment with
Z-VAD-FMK, DCIC, calpeptin, or TPCK did not block
hMutSK protein degradation, whereas proteasome inhibitors
MG132 and lactacystin fully inhibited hMutSK degradation
(Fig. 3A). In all cell lines tested, MG132 was able to inhibit
hMSH2 (Fig. 3A,B) and hMSH6 (Fig. 3A,C) protein degra-
dation, even so the e¡ect was less pronounced for the KG1a
cells due to the naturally longer half-lives of the proteins in
these cells. Moreover, treatment of U937 cells for 4 h with
MG132 or lactacystin (Fig. 3D) increased hMSH2 and
hMSH6 protein expression. Under our experimental condi-
tions, treatment with proteasome inhibitors did not induce
any cell death.
All these results strongly suggested that degradation of
hMutSK proteins is dependent on the proteasome pathway.
3.4. In vitro proteasome activity in human cell extracts
Since the di¡erences observed in hMutSK protein degrada-
tion could result from variations in the proteasome activity,
we determined the overall proteasome activity in the di¡erent
cell extracts by an in vitro assay. First, we checked that pro-
teasome inhibitors completely blocked this activity (data not
Fig. 2. A: hMSH2 and hMSH6 protein stability in human cell lines evaluated after cell incubation with 10 Wg/ml CHX at the indicated times.
Western blots of U937 and HL-60 cell extracts were overexposed in order to evaluate protein degradation. B: Densitometric analysis of
hMSH2 and hMSH6 protein levels normalized to L-actin expression. Results are expressed as percentages of untreated control cells. Linear re-
gression drawn in the graphs is calculated from the data. HL-60 cell exposure to CHX was limited to 10 h because of cytotoxic e¡ects. Each
data point is the mean (W S.D.) of three independent experiments.
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shown). Unexpectedly overall proteasome activity varied with
cell extracts but was lower in U937, HL-60 and HeLa than in
KG1a and MRC-5 cell extracts (Fig. 4).
Therefore, these results precluded the hypothesis of a higher
overall proteasome activity in U937 and HL-60 cell lines to
explain the low hMutSK protein expression levels.
3.5. Ubiquitination of hMutSK proteins
Based on the data shown above, we speculated that the
ubiquitination of hMutSK proteins prior to their degradation
could di¡er in the di¡erent cell lines. Following immunopre-
cipitation with anti-Ub antibody, hMSH2 and hMSH6 pro-
teins were recovered in the pool of ubiquitinated proteins in
U937 and HL-60 cells while only faint ubiquitination of
hMutSK was detected in KG1a, MRC-5 and HeLa cell lines
(Fig. 5). As these proteins associate as a dimer, we can con-
clude that at least one of the partners exists in ubiquitinated
form, more abundant in the U937 and HL60 cells than in
KG1a, HeLa or MRC-5 cells.
These results suggested that ubiquitination may be a limit-
ing step for hMutSK protein degradation in cells.
3.6. In vitro degradation of hMutSK proteins by the
Ub-dependent proteasome
In order to provide direct evidence that hMutSK proteins
were degraded by the Ub-proteasome pathway, we measured
the proteolysis of hMSH2 and hMSH6 proteins in an in vitro
proteasome model from RRL. As shown in Fig. 6, hMutSK
proteins from U937 cells were degraded only when both ATP
and Ub were added. As expected, MG132 completely blocked
Fig. 3. E¡ect of di¡erent protease inhibitors on hMutSK protein
stability in U937 cells (A), HL-60 and KG1a cell lines (B,C). When
indicated, cells were pretreated for 1 h with 20 WM Z-VAD-FMK,
20 WM DCIC, 50 Wg/ml calpeptin, 20 WM TPCK, 10 WM MG132
(MG), or 10 WM lactacystin (lacta). Cells were then incubated with
10 Wg/ml CHX during 20 h. Densitometric analysis of hMSH2 and
hMSH6 protein expression was performed. Results are expressed as
percentages of untreated control cells after normalization to L-actin
expression. Each data point is the mean (WS.D.) of three indepen-
dent experiments. *P6 0.05 and **P6 0.01 versus untreated cells.
D: E¡ect of proteasome inhibition on hMSH2 and hMSH6 protein
expression. U937 cells were treated with MG132 (20 WM) or lacta-
cystin (25 WM) for 4 h. L-Actin was used as loading control.
Fig. 4. Proteasome activity in human cell lines. Comparison of pro-
teasome activity was done using sLLVY-MCA hydrolysis with cell
extracts from di¡erent cell lines for 1 h at 37‡C. Each data point is
the mean of three independent experiments ( W S.D.). **P6 0.01 ver-
sus U937 cells.
Fig. 5. Ubiquitination of hMutSK proteins in human cell lines. Im-
munoprecipitation was performed using anti-Ub and anti-MSH6 (as
a control of the amount of hMutSK proteins) antibodies. Because of
di¡erences in basal hMutSK protein levels, immunoblots with anti-
MSH2 and anti-MSH6 antibodies were performed with 1.2 mg of
protein extracts from U937 and HL-60 cell lines and only 0.4 mg
from KG1a, MRC-5 and HeLa cell lines.
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hMutSK protein degradation. These results con¢rmed that
hMutSK proteins could be degraded in vitro by the Ub-pro-
teasome pathway. In contrast, in the presence of both ATP
and Ub, hMutSK proteins from KG1a cells were not de-
graded.
Altogether these results suggested that a defect in the Ub-
proteasome pathway could not account for the lack of
hMutSK protein ubiquitination and degradation observed in
KG1a cells.
4. Discussion
This study shows for the ¢rst time that the Ub-proteasome
complex is responsible for degradation of hMutSK proteins,
and that this process is e⁄ciently regulated in a cell-dependent
manner. Therefore, proteasome-mediated degradation could
play a major role in regulating hMutSK protein expression.
Since hMSH2 and hMSH6 protein degradation rates are very
similar, proteasome-mediated degradation could contribute to
maintain a constant ratio between these two proteins.
The di¡erences in protein degradation rates in the di¡erent
human cell lines seemed speci¢c for hMutSK proteins since
other proteins including p21/Waf1, that are also degraded
by the Ub-proteasome pathway [19], were degraded at the
same rate in U937, HL-60, MRC-5 and HeLa cells (data
not shown). These di¡erences could result from di¡erent
mechanisms. First, these cells may display di¡erent Ub-pro-
teasome activities. However, using an in vitro assay, we found
that overall proteasome activity did not correlate with
hMutSK protein degradation rate in the di¡erent cell lines.
Moreover, the degradation of hMutSK proteins immunopre-
cipitated from U937 and KG1a cells di¡ered signi¢cantly
when tested with the RRL system. These results argue against
the implication of Ub-proteasome activity in the regulation of
degradation rate. Second, the di¡erences in expression of
hMutSK proteins in U937 and KG1a cells could result from
di¡erences in their structure or conformation that would af-
fect their ubiquitination and degradation. Speci¢c protein^
protein interaction or phosphorylation has been shown to
in£uence structure or conformation of proteins, resulting in
modulation of ubiquitination [20]. As far as hMutSK is con-
cerned, the hypothesis of phosphorylation events is supported
by the presence of putative phosphorylation sites in hMutSK
proteins and by the recent demonstration that both hMSH2
and hMSH6 are substrates for various serine-threonine ki-
nases [21]. These hypotheses are under current investigation.
Although proteasome inhibitors were able to increase
hMutSK proteins, the recovery of hMutSK proteins was not
accompanied by increased hMutSK activity (data not shown),
suggesting that accumulated proteins were not active.
In cells displaying a high degradation rate of hMutSK pro-
teins, we have already shown that low hMutSK protein ex-
pression level is a limiting factor for MMR activity [16]. Con-
sequently, our present results suggest that the Ub-proteasome
pathway may also in£uence MMR activity. The participation
of the Ub-proteasome pathway in other DNA repair gene
expression and activity has been reported already [13^15].
Therefore, the Ub-proteasome pathway plays a role as one
of the regulators of DNA repair activities.
Acknowledgements: This work was supported by l’Association pour la
Recherche sur le Cancer (Grants 4460 and 5526 to G.L.). H.H.-P. is
the recipient of a grant from the Ministe're de l’Education Nationale,
l’Enseignement Supe¤rieur et la Recherche (MENESR).
References
[1] Hoeijmakers, J.H. (2001) Nature 411, 366^374.
[2] Boyer, J.C., Umar, A., Risinger, J.I., Lipford, J.R., Kane, M.,
Yin, S., Barrett, J.C., Kolodner, R.D. and Kunkel, T.A. (1995)
Cancer Res. 55, 6063^6070.
[3] Kolodner, R.D. and Marsischky, G.T. (1999) Curr. Opin. Genet.
Dev. 9, 89^96.
[4] Ward, R., Meldrum, C., Williams, R., Mokany, E., Scott, R.,
Turner, J., Hawkins, N., Burgess, B., Groombridge, C. and Spi-
gelman, A. (2002) J. Cancer Res. Clin. Oncol. 128, 403^411.
[5] Zhu, Y.M., Das-Gupta, E.P. and Russell, N.H. (1999) Blood 94,
733^740.
[6] Sheikhha, M.H., Tobal, K. and Yin, J.A. (2002) Br. J. Haematol.
117, 359^365.
[7] Scherer, S.J., Maier, S.M., Seifert, M., Hanselmann, R.G., Zang,
K.D., Muller-Hermelink, H.K., Angel, P., Welter, C. and
Schartl, M. (2000) J. Biol. Chem. 275, 37469^37473.
[8] Szadkowski, M. and Jiricny, J. (2002) Genes Chromosomes Can-
cer 33, 36^46.
[9] Humbert, O., Achour, I., Lautier, D., Laurent, G. and Salles, B.
(2003) Nucleic Acids Res. 31, 527^5634.
[10] Belloni, M., Uberti, D., Rizzini, C., Jiricny, J. and Memo, M.
(1999) J. Neurochem. 72, 974^979.
[11] Dosch, J., Christmann, M. and Kaina, B. (1998) Carcinogenesis
19, 567^573.
[12] Ciechanover, A. (1994) Cell 79, 13^21.
[13] Oren, M. (1999) J. Biol. Chem. 274, 36031^36034.
[14] Sweder, K. and Madura, K. (2002) J. Biomed. Biotechnol. 2, 94^
105.
[15] Xu-Welliver, M. and Pegg, A.E. (2002) Carcinogenesis 23, 823^
830.
[16] Humbert, O., Hermine, T., Hernandez, H., Bouget, T., Selves, J.,
Laurent, G., Salles, B. and Lautier, D. (2002) J. Biol. Chem. 277,
18061^18068.
[17] Grune, T., Blasig, I.E., Sitte, N., Rolo¡, B., Haselo¡, R. and
Davies, K.J. (1998) J. Biol. Chem. 273, 10857^10862.
[18] Nakajima, T., Morita, K., Ohi, N., Arai, T., Nozaki, N., Kiku-
chi, A., Osaka, F., Yamao, F. and Oda, K. (1996) J. Biol. Chem.
271, 24842^24849.
[19] Chang, Y.C., Lee, Y.S., Tejima, T., Tanaka, K., Omura, S.,
Heintz, N.H., Mitsui, Y. and Magae, J. (1998) Cell Growth Dif-
fer. 9, 79^84.
[20] Kubbutat, M.H., Jones, S.N. and Vousden, K.H. (1997) Nature
387, 299^303.
[21] Christmann, M., Tomicic, M.T. and Kaina, B. (2002) Nucleic
Acids Res. 30, 1959^1966.
Fig. 6. Degradation of hMSH2 and hMSH6 proteins by the activa-
tion of Ub proteolysis in in vitro assay. Aliquots of immunoprecipi-
tated hMSH6 and hMSH2 proteins from U937 and KG1a cell ex-
tracts were incubated with RRL. ATP, Ub and/or MG132 (MG)
were added as indicated. hMutSK proteins are detected by immuno-
blots.
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